#United States #Philadelphia #Signant Health #Ametris #ASCP 2026

Signant Health Engages with CNS Community at ASCP 2026 Following Ametris Acquisition

On May 19, 2026, Signant Health, a prominent provider of evidence generation solutions in clinical trials, made waves in the medical community by announcing its participation at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. This event is significant, especially following the company's recent strategic acquisition of Ametris, a pioneering entity in sensor-based clinical trial data collection.

During the ASCP conference, representatives from both Signant and Ametris will interact with industry leaders, researchers, and sponsors. Their goal is to harness collaborative discussions aimed at enhancing data quality and refining patient-centric approaches in clinical trial design. The merger of these two organizations brings together Signant's established proficiency in electronic clinical outcome assessments (eCOA) and patient engagement, combined with Ametris' innovative capabilities in sensor-derived data capture. This partnership represents a significant evolution toward continuous and objective data collection, which is especially critical in central nervous system (CNS) and other complex therapeutic applications.

Dawie Wessels, the Chief Medical Officer at Signant, commented on the importance of ASCP as a platform for advancing innovations in psychopharmacology and CNS research. He emphasized that their participation illustrates Signant's unwavering commitment to the scientific community, echoing their expanded capabilities as a unified organization post-Ametris acquisition.

The ASCP activities will culminate in a Strategic Advisory Board meeting hosted by Signant on the last day of the conference. This meeting will convene experts to deliberate on emerging challenges faced in clinical trial measurement, digital endpoints, and the integration of real-world evidence into clinical practices. Additionally, representatives from both organizations are slated to hold pre-scheduled meetings with sponsors and partners to discuss how their unified efforts can enhance trial outcomes, minimize variability, and create a solid foundation for regulatory and clinical decision-making.

Historically, CNS trials relied heavily on subjective rating scales, which often fail to capture the full spectrum of patient experiences. By integrating eCOA with continuous sensor-derived data from Ametris, Signant aims to provide sponsors and researchers with a clearer picture of patient experiences occurring between clinical site visits. These are critical moments where the effects of treatment are most pronounced yet rarely recorded.

To further explore the capabilities and offerings of the newly combined resources of Signant and Ametris, interested parties are encouraged to visit their dedicated page at Signant Health's Ametris Unified eCOA and Sensors.

The Future of Evidence Generation

As a leader in the evidence generation landscape, Signant Health applies software, extensive therapeutic expertise, and operational knowledge to provide quality evidence through various trial models—traditional, hybrid, and virtual. With a legacy spanning over 25 years, more than 600 sponsors, including all top 20 pharmaceutical companies, trust Signant Health for its comprehensive eClinical solutions. Their array of offerings, which incorporates clinical outcomes assessments, clinician ratings, cognitive testing, and wearable technologies, positions them at the forefront of the industry providing robust evidence generation capabilities.

In conclusion, Signant Health’s engagement at the ASCP 2026, alongside its strategic partnerships, marks a pivotal step in revolutionizing the landscape of data collection and clinical trial design, capturing the critical insights that drive better outcomes in CNS and beyond.